Jonathan Hannings
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jonathan Hannings has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Brian Alexander King
Office on Smoking and Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publications - Hyungsik Shin
Center for Tobacco Products, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, United States, 1 (888) 463-6332
2 shared publications - Matthew C. Farrelly
RTI International, Research Triangle Park, North Carolina
2 shared publications - Robin Toblin
Center for Tobacco Products, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, United States, 1 (888) 463-6332
2 shared publications - Xin Xu
Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland
2 shared publications - Zachary Cahn
Center for Tobacco Products, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, United States, 1 (888) 463-6332
2 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (9) , 1599-1603
Sales of cigarettes with WS-3, a synthetic cooling agent, in an area with a menthol cigarette sales prohibition
Introduction: The synthetic cooling agent WS-3 (N-ethyl-p-menthane-3-carboxamide) elicits a cooling sensation without a minty taste. In areas with menthol cigarette sales prohibitions, such as California, tobacco companies have marketed cigarettes with WS-3 as alternatives to menthol cigarettes. We examined sales of cigarettes with WS-3 in NielsenIQ’s Retail Measurement Services Pacific division, which includes the state of California. Methods: With NielsenIQ data, we estimated sales of cigarettes with WS-3 from June 2022 to March 2024. We compared the NielsenIQ Pacific division, which includes California and two less populous states (Washington and Oregon), to all other divisions combined. Within the Pacific division, we compared trends in sales of cigarettes with WS-3 to menthol cigarettes. Results: In our study period, cigarettes with WS-3 appeared in the NielsenIQ Pacific division approximately 2 weeks before the implementation of California’s menthol cigarette prohibition in December 2022 and did not appear elsewhere in substantive quantities (>5 cartons) until Spring 2023. Most (87.0%) sales of cigarettes with WS-3 during the study period occurred in the Pacific division, peaking near 19 000 weekly carton sales. Weekly sales of Pacific division menthol cigarettes dropped by more than 100 000 cartons in 2 months after California’s prohibition. Conclusion: In the Pacific division, California’s menthol cigarette prohibition appears to have moderately reduced sales of menthol cigarettes and spurred sales of cigarettes with WS-3. Observationally, these sales data suggest that cigarettes with WS-3 only partially displaced the declining sales of menthol cigarettes. Future research could examine reasons for and experiences using cigarettes with WS-3. Implications: Tobacco companies explicitly marketed cigarettes with the synthetic cooling agent WS-3 as replacements for menthol cigarettes. Sales data from NielsenIQ’s Pacific division suggest that California’s menthol cigarette prohibition may have reduced sales of menthol cigarettes and spurred the introduction of cigarettes with WS-3 into the marketplace. The findings suggest that sales of cigarettes with WS-3 did not fully offset the decrease in menthol cigarette sales.
- 17 April 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (9) , 1599-1603
Open AccessSales of cigarettes with WS-3, a synthetic cooling agent, in an area with a menthol cigarette sales prohibition
Introduction: The synthetic cooling agent WS-3 (N-ethyl-p-menthane-3-carboxamide) elicits a cooling sensation without a minty taste. In areas with menthol cigarette sales prohibitions, such as California, tobacco companies have marketed cigarettes with WS-3 as alternatives to menthol cigarettes. We examined sales of cigarettes with WS-3 in NielsenIQ’s Retail Measurement Services Pacific division, which includes the state of California. Methods: With NielsenIQ data, we estimated sales of cigarettes with WS-3 from June 2022 to March 2024. We compared the NielsenIQ Pacific division, which includes California and two less populous states (Washington and Oregon), to all other divisions combined. Within the Pacific division, we compared trends in sales of cigarettes with WS-3 to menthol cigarettes. Results: In our study period, cigarettes with WS-3 appeared in the NielsenIQ Pacific division approximately 2 weeks before the implementation of California’s menthol cigarette prohibition in December 2022 and did not appear elsewhere in substantive quantities (>5 cartons) until Spring 2023. Most (87.0%) sales of cigarettes with WS-3 during the study period occurred in the Pacific division, peaking near 19 000 weekly carton sales. Weekly sales of Pacific division menthol cigarettes dropped by more than 100 000 cartons in 2 months after California’s prohibition. Conclusion: In the Pacific division, California’s menthol cigarette prohibition appears to have moderately reduced sales of menthol cigarettes and spurred sales of cigarettes with WS-3. Observationally, these sales data suggest that cigarettes with WS-3 only partially displaced the declining sales of menthol cigarettes. Future research could examine reasons for and experiences using cigarettes with WS-3. Implications: Tobacco companies explicitly marketed cigarettes with the synthetic cooling agent WS-3 as replacements for menthol cigarettes. Sales data from NielsenIQ’s Pacific division suggest that California’s menthol cigarette prohibition may have reduced sales of menthol cigarettes and spurred the introduction of cigarettes with WS-3 into the marketplace. The findings suggest that sales of cigarettes with WS-3 did not fully offset the decrease in menthol cigarette sales.
- Open Access
- 12 March 2026
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 12 (1) , e81033
The Impact of US Food and Drug Administration’s Advisory and Enforcement Actions on US Sales of Esco Bars Products in 2023: Synthetic Control Approach
Background: In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among US middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the US Food and Drug Administration (FDA). On May 12, 2025, and May 25, 2023, the FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22, 2023, and July 27, 2023, the FDA also issued warning letters to US retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. Objective: We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. Methods: This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from the NielsenIQ Retail Measurement Service between January 1, 2023, and December 30, 2023. Data came from the 48 contiguous states and were not available for internet and vape shop sales. First, we standardized the data by transforming the weekly sales into z scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which the FDA did not take action during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. Results: By the last week of 2023, actual Esco Bars’ weekly sales were 68.5% lower than the estimated sales in the comparison group ( P =.02). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units ( P =.06). These findings were robust across sensitivity analyses. Conclusions: The FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the United States, with a sustained impact noted over a 5-month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.
- 12 March 2026
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 12 (1) , e81033
Open AccessThe Impact of US Food and Drug Administration’s Advisory and Enforcement Actions on US Sales of Esco Bars Products in 2023: Synthetic Control Approach
Background: In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among US middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the US Food and Drug Administration (FDA). On May 12, 2025, and May 25, 2023, the FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22, 2023, and July 27, 2023, the FDA also issued warning letters to US retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. Objective: We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. Methods: This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from the NielsenIQ Retail Measurement Service between January 1, 2023, and December 30, 2023. Data came from the 48 contiguous states and were not available for internet and vape shop sales. First, we standardized the data by transforming the weekly sales into z scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which the FDA did not take action during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. Results: By the last week of 2023, actual Esco Bars’ weekly sales were 68.5% lower than the estimated sales in the comparison group ( P =.02). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units ( P =.06). These findings were robust across sensitivity analyses. Conclusions: The FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the United States, with a sustained impact noted over a 5-month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.
- Open Access
- 5 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Impact of FDA Advisory and Enforcement Actions on U.S. Sales of Esco Bars Products in 2023 (Preprint)
BACKGROUND In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among U.S. middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the U.S. Food and Drug Administration (FDA). On May 12 and May 25, 2023, FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22 and July 27, 2023, FDA also issued warning letters to U.S. retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. OBJECTIVE We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. METHODS This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from NielsenIQ Retail Measurement Service between January 1 and December 30, 2023. Data came from the 48 contiguous states; data were not available for Internet and vape shop sales. First, we standardized the data by transforming weekly sales into Z-scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which FDA did not take actions during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. RESULTS By the last week of 2023, actual Esco Bars weekly sales were 68.5% lower than estimated sales in the comparison group (p=0.019). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units (p=0.058). These findings were robust across sensitivity analyses. CONCLUSIONS FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the U.S., with a sustained impact noted over a 5 month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.
- 5 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Impact of FDA Advisory and Enforcement Actions on U.S. Sales of Esco Bars Products in 2023 (Preprint)
BACKGROUND In 2023, Esco Bars was the second most commonly reported e-cigarette brand used among U.S. middle and high school student e-cigarette users. These products have not been authorized for sale in the United States by the U.S. Food and Drug Administration (FDA). On May 12 and May 25, 2023, FDA issued an import alert and a warning letter, respectively, to the manufacturer requiring them to immediately remove these unauthorized products from the market. On June 22 and July 27, 2023, FDA also issued warning letters to U.S. retailers and distributors, respectively, regarding the illicit sale of these unauthorized products. This study evaluated the impact of these advisory and enforcement actions on retail sales of Esco Bars in the United States. OBJECTIVE We evaluated the impact of these 2023 FDA advisory and enforcement actions on illicit sales of unauthorized Esco Bars to better inform future regulatory decision-making. METHODS This study used a synthetic control method to evaluate the impact of 2023 FDA advisory and enforcement actions on Esco Bars sales based on weekly sales data from NielsenIQ Retail Measurement Service between January 1 and December 30, 2023. Data came from the 48 contiguous states; data were not available for Internet and vape shop sales. First, we standardized the data by transforming weekly sales into Z-scores. Second, we created a synthetic comparison for Esco Bars sales based on sales of other e-cigarettes for which FDA did not take actions during the analytical period. Finally, we calculated the difference in sales between Esco Bars and the comparison group before and after the FDA actions. To assess the robustness of the findings, we used other standardization methods for sensitivity analyses. RESULTS By the last week of 2023, actual Esco Bars weekly sales were 68.5% lower than estimated sales in the comparison group (p=0.019). Over the 5-month period following FDA advisory and enforcement actions, Esco Bars product sales were reduced by approximately 1.7 million equivalized units (p=0.058). These findings were robust across sensitivity analyses. CONCLUSIONS FDA’s advisory and enforcement actions substantially reduced sales of Esco Bars products in the U.S., with a sustained impact noted over a 5 month period. These findings underscore the importance and impact of FDA actions against unauthorized tobacco products as part of a comprehensive regulatory approach.